Psychiatric Times

03/16/2026

📝 Get your submissions in by March 31, 2026!

Submit to our writing contest on use of the PRiSM instrument for the opportunity to win publication in Psychiatric Times and a $500 prize. Guidelines here:

Submit to our writing contest for the opportunity to win publication in Psychiatric Times and a $500 prize!

03/13/2026

Catatonia management typically involves 3 domains: targeting the syndrome of catatonia, addressing associated conditions or contributory substances, and preventing medical and functional complications.
https://www.psychiatrictimes.com/view/catatonia-where-we-are-and-whats-next

03/10/2026

PTSD may not present in a prototypical manner and may become further exacerbated within different ethnic groups or communities that experience sustained violence and trauma, thus increasing the risk of underdiagnosis or misdiagnosis.

Chronic community violence reshapes PTSD—often masking it as depression or ADHD. Learn why culturally responsive, trauma-informed diagnosis matters.

03/05/2026

New study findings suggest that 6 months of dialectical behavioral therapy are superior to SSRI treatment in reducing suicidal thoughts and behaviors and nonsuicidal self-injury in individuals with borderline personality disorder—even in a population with a high rate of major depressive disorder comorbidity.

New RCT shows DBT cuts suicidal crises and self-harm in borderline personality disorder more than SSRIs, though benefits fade after treatment.

03/03/2026

Our March theme: Hormones & Psychiatry.

If you are interested in being featured in a future Special Report/print issue, submit to our content series! https://www.psychiatrictimes.com/view/presenting-our-march-2026-theme-hormones-psychiatry

03/03/2026

Early bird pricing for SoCal Psych is now available.

Join colleagues from across the region for two days of timely clinical insights, expert-led discussions, and practical takeaways you can bring back to your practice.

Register now: https://hubs.li/Q045fQPK0

03/02/2026

The March issue of Psychiatric Times is now live! This month, we take closer look at the future DSM and changes from previous editions.

Download the issue now and follow along as articles are shared throughout the month.https://cdn.sanity.io/files/0vv8moc6/psychtimes/0be40de8906170b7405945a3e66e281646748678.pdf

02/26/2026

Weight bias can obscure eating disorders in all body sizes. This National Eating Disorder Awareness Week, learn more about evolving epidemiology, diagnostic challenges, and the importance of universal screening for eating disorders from Molly Perlman, MD, MPH, CEDS-C, the chief medical officer of Monte Nido.

Weight bias can obscure eating disorders in all body sizes; learn why early screening, asking questions, and trauma care change outcomes.

02/25/2026

"Relapse is an expected feature of illness, not a moral failure."

Learn more on why repeat psychiatric admissions persist and what care teams can do to break the cycle:

Why repeat psychiatric admissions persist, plus what hospital teams can do to break the cycle.

02/24/2026

The "baby goose bonding theory" suggests M**A reopens social plasticity, fostering trust and emotional openness, which are crucial for trauma integration and the reduction of PTSD symptoms.

How does M**A-assisted therapy rewire fear circuits in PTSD and boost trust? Why has the FDA asked for more safety data? Learn more in this Special Report.

02/23/2026

Eating disorders are complex — and emerging research suggests dermatologic conditions like acne may be associated with increased risk.

During National Eating Disorder Awareness Week, we’re highlighting findings clinicians should be aware of, including the potential link between acne and eating disorder risk.

Read more: https://hubs.li/Q0443lN60

02/20/2026

The FDA has accepted Teva Pharmaceuticals' NDA for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of adults with schizophrenia.

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.